Glomerulosclerosis, Focal Segmental: all 100 studies

Page 1 of 1. Open to participants first (32), then studies with results posted, then the rest; newest registration first within each.

• MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)Not yet recruitingNCT07892651
• A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change DiseaseNot yet recruitingNCT07861113Phase 2
• Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Phase 2
• SLIT ABS: Study on Patients With Autoimmune PodocytopathyRecruitingNCT07516964Not applicable
• A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental GlomerulosclerosisRecruitingNCT07499700Phase 2/3
• A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)RecruitingNCT07268638Phase 2
• A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)RecruitingNCT07220083Phase 3
• Epithelial Dysmetabolism and Renal Fibrosis in ANCA VasculitisRecruitingNCT07010250
• Raman Spectroscopy Diagnosis of Kidney DiseasesRecruitingNCT06760845
• An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte DiseasesRecruitingNCT06664814Phase 2
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingNCT06500702Phase 2
• Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1Not yet recruitingNCT06443034
• Autoantibodies Against-nephrin in Idiopathic Nephrotic SyndromeRecruitingNCT06334692
• Circulating Factors in Nephrotic SyndromeNot yet recruitingNCT06315504
• ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and BiobankRecruitingNCT06162546
• AMPK-activation by Metformin in FSGS: AMP-FSGSRecruitingNCT06090227Phase 1/2
• National Registry of Rare Kidney DiseasesRecruitingNCT06065852
• A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsRecruitingNCT05942625Phase 1
• Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change DiseaseRecruitingNCT05650619
• taVNS for FRNS in ChildrenRecruitingNCT05588063Not applicable
• A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)RecruitingNCT05583942Not applicable
• Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.RecruitingNCT05505500
• A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARBRecruitingNCT05183646Phase 3
• Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingNCT05003986Phase 2
• INS, B Cells and MicrobiotaRecruitingNCT04924712
• NEPTUNE Match StudyRecruitingNCT04571658Not applicable
• Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 SystemRecruitingNCT04065438Not applicable
• The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)RecruitingNCT03949972
• KOrea Renal Biobank NEtwoRk System TOward NExt-generation AnalysisRecruitingNCT03929887
• Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in ChildrenRecruitingNCT02235857Not applicable
• Nephrotic Syndrome Study NetworkRecruitingNCT01209000
• Proteinuria in Pre and Post TransplantRecruitingNCT01094327
• Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental GlomerulosclerosisCompletedNCT04340362Phase 2Results posted
• Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseCompletedNCT04009668Phase 2Results posted
• A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic SyndromeTerminatedNCT03703908Phase 2Results posted
• Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental GlomerulosclerosisTerminatedNCT03598036Phase 2Results posted
• A Study of CCX140-B in Subjects With FSGSCompletedNCT03536754Phase 2Results posted
• Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT03493685Phase 3Results posted
• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)TerminatedNCT03448692Phase 2Results posted
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedNCT03366337Phase 2Results posted
• Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsCompletedNCT02921789Phase 2Results posted
• Acthar for Treatment-Resistant or Treatment-Intolerant ProteinuriaCompletedNCT02633046Phase 4Results posted
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)CompletedNCT02592798Phase 2Results posted
• A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT02000440Phase 2Results posted
• Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisCompletedNCT01613118Phase 2Results posted
• A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGSCompletedNCT01573533Phase 2Results posted
• Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTHCompletedNCT01155141Phase 4Results posted
• Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney DiseaseTerminatedNCT01129557Phase 4Results posted
• Oral Galactose in Children With Steroid Resistant Nephrotic SyndromeCompletedNCT01113385Not applicableResults posted
• Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialCompletedNCT00814255Phase 2Results posted
• Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)CompletedNCT00135811Phase 3Results posted
• Podocyte RetinoidsCompletedNCT00098020Phase 2Results posted
• Permeability Factor in Focal Segmental GlomerulosclerosisCompletedNCT00007475Phase 1/2Results posted
• Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)CompletedNCT00001959Phase 2Results posted
• Immunophenotyping Profiling in Patients With Primary Nephrotic SyndromeCompletedNCT07702981
• Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisActive, not recruitingNCT07219121Phase 4
• REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)Active, not recruitingNCT06635720Phase 3
• Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic ImpairmentCompletedNCT06529796Phase 1
• A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147CompletedNCT05955872Phase 1
• Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)TerminatedNCT05441826Phase 2
• Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental GlomerulosclerosisCompletedNCT05267262Phase 2
• Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseaseCompletedNCT05237388Phase 2
• Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)CompletedNCT05200871
• Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruitingNCT04573920Phase 2
• Global Kidney Patient Trials NetworkCompletedNCT04389827
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseTerminatedNCT04387448Phase 2
• Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change DiseaseCompletedNCT04369183
• A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)TerminatedNCT04235621
• LDL-Apheresis for FSGS CardioRenal OutcomesCompletedNCT04088799
• PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantCompletedNCT03763643Early Phase 1
• Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving IrbesartanCompletedNCT03649152Phase 2
• FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT03422510Phase 2
• Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic SyndromeStatus unknownNCT03298698Phase 3
• Predictors of Disease Progression in Primary Focal Segmental GlomerulosclerosisCompletedNCT03126201
• Valproic Acid for Idiopathic Nephrotic SyndromeStatus unknownNCT02896270Phase 2/3
• Stem Cell Therapy for Patients With Focal Segmental GlomerulosclerosisCompletedNCT02693366Phase 1
• Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial EffectsCompletedNCT02585804Phase 4
• Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)Status unknownNCT02382874Phase 1
• Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney FailureActive, not recruitingNCT02194582
• A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT01665391Phase 2
• The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental GlomerulosclerosisTerminatedNCT01451489Not applicable
• Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200Not applicable
• Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT00981838Phase 3
• Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental GlomerulosclerosisStatus unknownNCT00956059Not applicable
• Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental GlomerulosclerosisTerminatedNCT00883636
• Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5WithdrawnNCT00816504Phase 1
• Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability FactorTerminatedNCT00816478Phase 1
• Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental GlomerulosclerosisCompletedNCT00801463Not applicable
• Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)TerminatedNCT00782561Phase 1
• Rituximab Treatment of Focal Segmental GlomerulosclerosisWithdrawnNCT00550342Phase 2
• Evaluation of Albuminuria HIV-Infected PatientsCompletedNCT00524992
• Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGSCompletedNCT00464321Phase 1
• Mycophenolate Mofetil in Membranous Nephropathy and Focal SegmentalCompletedNCT00404833Phase 3
• Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal GraftCompletedNCT00353535Phase 1
• Tacrolimus Treatment of Patients With Idiopathic Focal Segmental GlomerulosclerosisWithdrawnNCT00302536Not applicable
• Kidney Disease BiomarkersCompletedNCT00255398
• Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)CompletedNCT00193648Phase 1
• Sirolimus for Focal Segmental GlomerulosclerosisCompletedNCT00040508Phase 2
• Once-A-Month Steroid Treatment for Patients With Focal Segmental GlomerulosclerosisCompletedNCT00004990Phase 2
• Genetic Markers for Focal Segmental GlomerulosclerosisCompletedNCT00001393

← Glomerulosclerosis, Focal Segmental overview